EpiCept is focused on developing novel therapies in the areas of pain and cancer.

Cancer

In the area of cancer, EpiCept is seeking regulatory approval in Europe for Ceplene™ as remission maintenance therapy for the treatment of Acute Myeloid Leukemia (AML) and is utilizing its biopharmaceutical discovery capabilities for the discovery and advancement of apoptosis inducers, which are designed to address unmet medical needs in oncology, with two candidates advanced to clinical trials.

Pain

In the area of pain, the Company is advancing prescription pain products that use a topical delivery approach, as opposed to systemic or injectable modes, for both acute and chronic pain.

EpiCept invites you to learn more about these product candidates and their potential benefits to patients.

Deep Late Stage Development Pipeline